OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China	4728
Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019	685
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza	418
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis	347
Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia	297
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children	287
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome	266
Burden of Neurological Disorders Across the US From 1990-2017	243
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomize	239
Positron Emission Tomography Imaging With [¹⁸F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes	236
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease	230
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy	223
Association of Delirium With Long-term Cognitive Decline	217
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	217
Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry	216
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations	204
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	194
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia	191
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	186
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders	170
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease	170
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals	163
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping	163
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome	158
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β	150

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens	146
Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy	144
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease	140
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel	140
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease	140
The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection	138
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex	136
Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans	135
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	133
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy	132
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders	131
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab	129
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study	128
Association Between Cardiovascular Disease and Long-term Exposure to Air Pollution With the Risk of Dementia	126
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	124
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis	124
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	121
Global Prevalence of Young-Onset Dementia	119
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	116
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	114
Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis	113
Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome	113
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	108
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes	107
Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults	106
Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders	105
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease	105
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease	103
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	101
Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated Stroke	100
Global Prevalence and Incidence of Tinnitus	99
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	98
Assessment of the Predictive Value of Outpatient Smartphone Videos for Diagnosis of Epileptic Seizures	96
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study	94
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	94
Association of Time Since Injury to the First Clinic Visit With Recovery Following Concussion	94
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis	91
Seizure Cycles in Focal Epilepsy	90
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome	89
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders	87
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	87
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	86
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets	86
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes	85
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension	85
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis	85
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis	84
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability	81
Blood Pressure Thresholds and Neurologic Outcomes After Endovascular Therapy for Acute Ischemic Stroke	81
Continuous vs Routine Electroencephalogram in Critically Ill Adults With Altered Consciousness and No Recent Seizure	81

Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US	80
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease	80
Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke	77
Prevalence of High-risk Plaques and Risk of Stroke in Patients With Asymptomatic Carotid Stenosis	76
Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players	76
Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease	75
Prognostic Value of Spreading Depolarizations in Patients With Severe Traumatic Brain Injury	75
Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography	75
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis	74
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis	74
Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events	74
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	73
Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume	73
Association of NO₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease	72
Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US	72
Recovery of Consciousness and Functional Outcome in Moderate and Severe Traumatic Brain Injury	71
Autoimmune Encephalitis Misdiagnosis in Adults	71
Association of Sleep-Disordered Breathing With Alzheimer Disease Biomarkers in Community-Dwelling Older Adults	69
Comparison of 3 Treatment Strategies for Medication Overuse Headache	69
Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000-2016	67
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease	67
Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy	66
Association of NOTCH2NLC Repeat Expansions With Parkinson Disease	66
Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy–Related Inflammation	66
Association ofKlotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who CarryAPOE4	66
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US	65
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis	65
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy	64
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination	64
Association of Circadian Abnormalities in Older Adults With an Increased Risk of Developing Parkinson Disease	63
Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone	63
Comparison of Prehospital Scales for Predicting Large Anterior Vessel Occlusion in the Ambulance Setting	62
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke	62
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease	62
Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK	61
What the Aducanumab Approval Reveals About Alzheimer Disease Research	61
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease	61
Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses	60
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab	60
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California	60
Encephalitis Induced by Immune Checkpoint Inhibitors	59
Addressing Health Disparities Among Minority Populations	57
Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction	56
Association of Stress-Related Disorders With Subsequent Neurodegenerative Diseases	56
Assessing Brain Capillaries in Coronavirus Disease 2019	55
Hypoxic-Ischemic Encephalopathy Evaluated by Brain Autopsy and Neuroprognostication After Cardiac Arrest	54
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease	54
Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals	53
Safety and Efficacy of Intra-arterial Urokinase After Failed, Unsuccessful, or Incomplete Mechanical Thrombectomy in Anterior Circulation Large-Vessel Occlusion Stroke	52
Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury	52
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	52
Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults	52
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers	52
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment	51
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England	51
Assessment of Incidence and Risk Factors of Intracerebral Hemorrhage Among Participants in the Framingham Heart Study Between 1948 and 2016	51
Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke	51
Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis	51
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures	50
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease	50
Surgical Decompression for Space-Occupying Hemispheric Infarction	49
Spatial and Temporal Pattern of Ischemia and Abnormal Vascular Function Following Traumatic Brain Injury	49
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease	49
Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder	49
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	49
Implementation of a Prehospital Stroke Triage System Using Symptom Severity and Teleconsultation in the Stockholm Stroke Triage Study	48
Estimates of the Association of Dementia With US Mortality Levels Using Linked Survey and Mortality Records	48
Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure	47
Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS)	46
Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging	46
Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease	45
Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion	45
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment	45
Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study	45
Long-term Risk of Parkinson Disease Following Influenza and Other Infections	44
Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans	44
Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations	44
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes	44
Research Criteria for the Behavioral Variant of Alzheimer Disease	44
Association of Early-Life Cognitive Enrichment With Alzheimer Disease Pathological Changes and Cognitive Decline	43

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis	43
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	43
Association of Racial Residential Segregation Throughout Young Adulthood and Cognitive Performance in Middle-aged Participants in the CARDIA Study	42
Distributional Validity and Prognostic Power of the National Institutes of Health Stroke Scale in US Administrative Claims Data	42
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults	41
Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset	41
Association of Hearing Aids and Cochlear Implants With Cognitive Decline and Dementia	41
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome	41
Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease	41
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis	40
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease	40
Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy	40
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis	40
Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies	40
Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease	40
Hookworm Treatment for Relapsing Multiple Sclerosis	39
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy	39
Six Action Steps to Address Global Disparities in Parkinson Disease	39
Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease	39
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention	39
Neurologic Prognostication After Cardiac Arrest Using Brain Biomarkers	38
Association of Dermatomyositis Sine Dermatitis With Anti–Nuclear Matrix Protein 2 Autoantibodies	38
Paramagnetic Rim Sign in Radiologically Isolated Syndrome	38
Huntingtin-Lowering Therapies for Huntington Disease	38
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis	38
Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2	38
General Anesthesia vs Local Anesthesia in Microelectrode Recording–Guided Deep-Brain Stimulation for Parkinson Disease	37
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	37
Antiseizure Medication Concentrations During Pregnancy	37
Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era	37
A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage	37
Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury	37
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort	36
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis	36
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source	36
Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy	36
Endovascular Treatment After Stroke Due to Large Vessel Occlusion for Patients Presenting Very Late From Time Last Known Well	36
Prognosis of Asymptomatic Intracranial Stenosis in Patients With Transient Ischemic Attack and Minor Stroke	36
Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation for Chronic Back and Leg Pain	36
Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis	35
Risk of Rupture After Intracranial Aneurysm Growth	35
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability	35
Sex-Specific Association of the X Chromosome With Cognitive Change and Tau Pathology in Aging and Alzheimer Disease	34
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies	34
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis	34
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment	34
Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis	34
Effect of Motor Skill Training in Functional Activities vs Strength and Flexibility Exercise on Function in People With Chronic Low Back Pain	34
Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity	34
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US	33
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia	33
Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase	33
A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack	33
Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms	33
Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke	32
Prevalence of Incidentally Detected Signs of Intracranial Hypertension on Magnetic Resonance Imaging and Their Association With Papilledema	32
Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy	32
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	32
DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease	32
Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management	32
Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic	32
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease	31
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus	31
Assessment of Recurrent Stroke Risk in Patients With a Carotid Web	31
Freezing of Gait and Its Levodopa Paradox	31
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease	31
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome	31
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	30
Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke	30
Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies	30
Evaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months	30
Prediction of Long-term Survival After Status Epilepticus Using the ACD Score	29
Neurologic Complications of Smallpox and Monkeypox	29
US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?	29
Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes	28
Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children	28
Suicidality Risk of Newer Antiseizure Medications	28
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease	28
Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment	28
Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 Patients	27
Opportunities for Prevention of Concussion and Repetitive Head Impact Exposure in College Football Players	27
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective	27
Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials	27
Assessment of Telestroke Capacity in US Hospitals	27
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice	26
Trends in Antihypertensive Medication Use Among Individuals With a History of Stroke and Hypertension, 2005 to 2016	26
Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage	26
Factors Contributing to Major Neurological Complications From Vein of Galen Malformation Embolization	25
Association of APOE Genotypes and Chronic Traumatic Encephalopathy	25
Sexual and Gender Minority Health in Neurology	25
Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care	25
Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion	25
Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source	25
Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy	25
Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well	25